COGNITION THERAPEUTICS INC
CGTXNASDAQTrading Snapshot
- Day Range
- $145.31 – $149.95
- 52-Week Range
- $0.55 – $2.05
- Volume
- $4.48B
- Avg Volume
- $5.15B
- Shares Outstanding
- 89.5M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $13M
- Last Q Revenue
- $3M
- P/E Ratio
- -4.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.19
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +91.5%
Why Investors Own CGTX
- ✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
COGNITION THERAPEUTICS INC
CGTX
StockOtter · stockotter.spaceAbout COGNITION THERAPEUTICS INC
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
COGNITION THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CGTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
COGNITION THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.